The Value of Hybrid Interstitial Tandem and Ring Applicators for Organ at Risk Dose Reduction in Small Volume Cervical Cancer

MRI-based, image guided adaptive brachytherapy is now the standard of care for cervical cancer. There is increasing interest in the use of hybrid intracavitary/interstitial applicators for dose escalation in bulky tumors (HR-CTV>30 cc) as currently recommended in the EMBRACE II trial. The value of hybrid intracavitary/interstitial applicators for tumors with smaller HR-CTV is less certain. The purpose of this study is to evaluate the organ at risk sparing of hybrid applicators (Hybrid TR) compared to conventional tandem and ring(TR) applicators.
Source: Brachytherapy - Category: Cancer & Oncology Authors: Source Type: research